Protective effect of crocetin from *Crocus sativus* L. on myocardial ischemia-reperfusion injury in rats

Chengxiao LIU¹,²*, Erlian SUN²**, Wenjun MENG¹, Guoqing SUN¹

**Abstract**

This study investigated the protective effect of crocetin from *Crocus sativus* L. on myocardial ischemia-reperfusion injury (MIRI) in rats. Sixty SD rats were randomly divided into sham-operated, model, and low-, medium- and high-dose crocetin groups. Later 3 groups were intragastrically administrated with 10, 20 and 40 mg/kg crocetin from *Crocus sativus* L., respectively, for 1 week. On the 8th day, the MIRI model was established in the later 4 groups. The blood biochemical indexes, hemodynamic indexes, myocardial infarct size, myocardial antioxidant indexes and myocardial expressions of B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein (Bax), serine/threonine kinase (Akt) and phosphorylated Akt (p-Akt) protein were determined. Results showed that, compared with model group, in high-dose crocetin group the left ventricular systolic pressure, +d*p/dt*max and -d*p/dt*max, myocardial superoxide dismutase and glutathione peroxidase levels, and myocardial Bcl-2/Bax ratio and p-Akt/Akt ratio were significantly increased, and the left ventricular end diastolic pressure, myocardial infarct size, serum lactate dehydrogenase, creatine kinase-MB, cardiac troponin I, tumor necrosis factor-α, interleukin-1β, interleukin-6 and malondialdehyde levels were significantly decreased (all P < 0.05). In conclusion, crocetin from *Crocus sativus* L. has protective effects on MIRI in rats.

**Keywords:** crocetin; ischemia-reperfusion injury; Bcl-2; Bax; Akt.

**Practical Application:** Crocetin from *Crocus sativus* L. has potential for clinical prevention of myocardial ischemia-reperfusion injury.

1 Introduction

With the increase of elderly population proportion and the improvement of people’s living standard, the incidence of ischemic heart disease is increasing year by year. In recent years, although the vascular recanalization and reconstruction techniques such as thrombolysis, interventional therapy and coronary artery bypass grafting can quickly restore the coronary perfusion, the incidence of myocardial ischemia-reperfusion injury (MIRI) is still high, and it has become an important cause of death in ischemic heart disease (Venardos et al., 2007). MIRI can lead to the myocardial irreversible damage, and cause the myocardial morphological changes. It is characterized by myocardial fiber rupture, arrangement disorder, interstitial edema and inflammatory cell infiltration (Zhai et al., 2000; Wang et al., 2018). The mechanism of MIRI may involve oxidative stress and inflammatory reaction (Cheng et al., 2015; Hu et al., 2015). How to effectively delay and control the occurrence and development of MIRI is an urgent problem in the prevention and treatment of ischemic heart disease. Crocetin is the active substance extracted from the stigma of *Crocus sativus* L., a popular traditional Chinese medicine. Previous study has proved that, crocin has obvious antiatherogenic and anti-hypertension effect (Rameshrad et al., 2018). In addition, crocetin has protective effects on myocardium, and its mechanism may be related to its anti-lipid peroxidation, inhibition of free radical production and calcium overload, and inhibition of cardiomyocyte apoptosis (Shen et al., 2006; Zhang et al., 2009). However, the action mechanism of crocin on myocardial ischemia is not very clear. It is reported that, the inflammatory response and oxidative stress are involved in the occurrence and development of MIRI (Vinten-Johansen et al., 2007; Yu et al., 2016). This study investigated the protective effect of crocetin on MIRI in rats and the related mechanisms. The objective was to provide a experimental basis for the development of crocetin related medicines and the clinical prevention and treatment of MIRI.

2 Materials and methods

2.1 Animal grouping and treatment

Sixty Sprague-Dawley rats (250 ± 20 g) were randomly divided into 5 groups: sham-operated group, model group, and low-, middle- and high-dose crocetin groups, 12 rats in each group. The rats in low-, middle- and high-dose crocetin groups were intragastrically administrated with crocetin (extracted from the stigma of *Crocus sativus* L.; HPLC purity ≥ 98%), with dose of 10, 25 and 40 mg/kg, respectively (according to the results of pre-experiments). The rats in sham-operated and model groups were intragastrically administrated with normal saline. The intraperitoneal injection was performed once per day, and was continued for 1 week before MIRI modeling.
2.2 Establishment of MIRI model

According to the reported method (Liang et al., 2010), rats were anaesthetized by intraperitoneal injection of 10% chloral hydrate (300 mg/kg) and were fixed in supine position. After shearing, the neck was incised and the right carotid artery was isolated. The trachea was exposed and incised, and the mechanical ventilation was performed using small-animal ventilator. The breathing frequency was controlled at about 70 time/min. The electrodes were subcutaneously inserted in the extremities, and were connected with the biological function experiment system. The skin on the left margin of sternum was longitudinally incised. The chest between the fourth and fifth ribs was opened. The pericardium was cut, and the heart was fully exposed. A 5-0 silk was used to cross the surface layer of heart (depth of about 1.5 mm) at the position 2 mm under left atrium. The anterior descending branch of left coronary artery was ligated for inducing myocardial ischemia for 30 min. Then, the ligation was released for reperfusion for 2 h. The signs of successful MIRI establishment were as follows: in ischemia, the local myocardium was pale or purple, and in electrocardiogram the ST-segment was obviously elevated or T wave was elevated; in reperfusion, the ischemic myocardium turned red, and elevated ST segment decreased by more than 50%. In sham-operated group, the silk crossed the surface layer of heart, but the anterior descending branch of left coronary artery was not ligated, which lasted for 2 h.

2.3 Detection of hemodynamic indexes

After establishment of MIRI model, the cervical lymph nodes of rats were removed, and the right carotid artery was isolated. PE50 artery catheter was inserted into the left ventricle via right carotid artery. The left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), maximum rate of left ventricular pressure rise (+dp/dt max) and maximum the rate of decline (-dp/dt max) were recorded detected by MD3000 biological function experiment system (Anhui Zhenghua Biological Instrument Equipment Co., Ltd., Huaibei, China).

2.4 Determination of serum biochemical indexes

Rats were anesthetized using 2% sodium pentobarbital (Sigma-Aldrich Corp., MO, USA) by intraperitoneal injection (20 mg/kg). The abdominal cavity was opened. The blood of the abdominal aorta was taken, followed by centrifugation at 2000 rpm for 10 min. The serum lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) were detected using the spectrophotometry. The serum lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) were detected using enzyme linked immunosorbent assay. The procedures were in accordance to the instructions of kits (Shanghai Sangon Biological Engineering Technology And Service Co., Ltd., Shanghai, China).

2.5 Determination of myocardial infarction size

According to the reported method (Haugan et al., 2006), the heart was cut from the tip to the base, with the direction parallel to atrioventricular sulcus. The left ventricle was chopped, and was incubated in 1% 2,3,5-triphenyl tetrazolium chloride solution for 15 min. After staining, the infarcted myocardium presented pale, and the active myocardium presented red. The unstained non-ischemic area was separated from the red-stained ischemic area with an operating blade. The infarct volume of the red-stained myocardium was measured in a vessel with buffered liquid. The myocardial infarction size was presented by the ratio of infarcted area volume to total left ventricular volume.

2.6 Determination of myocardial superoxide dismutase, glutathione peroxidase and malondialdehyde levels

The heart of rats was taken, followed by rinsing with saline. The 10% myocardial homogenate was prepared. After centrifugation at 2000 rpm for 10 min, the supernatant was obtained. The superoxide dismutase (SOD) level was detected by xanthine oxidase method (Chen et al., 2016). The glutathione peroxidase (GSH-Px) level was measured by reduced glutathione depletion method (Fläringer et al., 2003). The content of malondialdehyde (MDA) was analyzed by thiobarbituric acid colorimetric assay (Chen et al., 2016).

2.7 Determination of myocardial Bcl-2, Bax, Akt and p-Akt protein expressions

The myocardial tissue was homogenized, and the protein was extracted using RIPA lysis buffer (Sigma-Aldrich Corp., MO, USA). The protein concentration was determined by Coomassie brilliant blue method. The 10% SDS-PAGE (Sigma-Aldrich Corp., MO, USA) was performed for 3 h, then the separated protein was transferred to the PVDF membrane (Sigma-Aldrich Corp., MO, USA). After washing the membrane with PBS (Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, China) for 3 times, 5% evaporated milk (Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, China) was used to block the non-specific antigen for 2 h. After blocking, the membranes were incubated with primary antibody overnight at 4°C, followed by washing with PBS. The horseradish peroxidase-labeled secondary antibody was added, followed by incubation at room temperature for 2 h. Visualization was accomplished by the enhanced chemiluminescence (ECL plus Western-blotting detection system, GE Healthcare Life Sciences, MA, USA). The intensity of bands was calculated with Image J 1.46 analysis software (European Molecular Biology Laboratory Inc., Oxford, UK). β-actin was used as the internal reference. The B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein (Bax), serine/threonine kinase (Akt) and phosphorylated serine/threonine kinase (p-Akt) primary antibodies and secondary antibodies were provided by Fuzhou Maixin Biotechnology Development Co., Ltd. (Fuzhou, China).

2.8 Statistical analysis

Data were presented as mean ± SD, and analyzed using SPSS 22.0 software (SPSS Inc., Chicago, IL, USA). The comparisons among different groups were performed using single-factor analysis of variance test with SNK-q test. P < 0.05 was considered as statistically significant.
3 Results

3.1 Effects of crocetin on hemodynamics of MIRI rats

As shown in Table 1, the LVEDP in model group was significantly higher than sham-operated group (P < 0.05), and the LVSP, (+dp/dt)max and (-dp/dt)max in model group were significantly lower than sham-operated group, respectively (P < 0.05). Compared with model group, the LVEDP in 3 crocetin groups was significantly decreased, respectively (P < 0.05), the LVSP and (+dp/dt)max in high-dose crocetin group, and the (-dp/dt)max in middle- and high-dose crocetin groups were significantly increased, respectively (P < 0.05).

3.2 Effects of crocetin on myocardial infarction size of MIRI rats

Figure 1 showed that, there was no obvious myocardial infarction in sham-operated group. The myocardial infarction size in middle- and high-dose crocetin groups was 36.5 ± 4.1% and 27.6 ± 3.2%, respectively, significantly lower than 46.1±5.8% in model group, respectively (P < 0.05).

3.3 Effects of crocetin on myocardial injury markers of MIRI rats

Compared with sham-operated group, the serum LDH, CK-MB and cTnO levels in rats in model group were significantly increased, respectively (P < 0.05). Compared with model group, the LDH level in middle- and high-dose crocetin groups, CK-MB level in high-dose crocetin groups, and cTnI level in 3 crocetin groups were significantly decreased, respectively (P < 0.05) (Table 2).

3.4 Effects of crocetin on serum TNF-α, IL-1β and IL-6 levels in MIRI rats

As shown in Table 3, compared with sham-operated group, the serum TNF-α, IL-1β and IL-6 levels in model group were significantly increased, respectively (P < 0.05). Compared with

Table 1. Hemodynamics of rats in different groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>LVSP (mmHg)</th>
<th>LVEDP (mmHg)</th>
<th>(+dp/dt)max (mmHg)</th>
<th>(-dp/dt)max (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham-operated</td>
<td>139.5 ± 27.1</td>
<td>3.5 ± 0.9</td>
<td>4078.3 ± 432.8</td>
<td>3678.9 ± 421.7</td>
</tr>
<tr>
<td>Model</td>
<td>93.3 ± 18.3</td>
<td>11.9 ± 2.3</td>
<td>2633.6 ± 367.3</td>
<td>2034.0 ± 389.3</td>
</tr>
<tr>
<td>Low-dose crocetin</td>
<td>97.2 ± 20.7</td>
<td>8.2 ± 1.8</td>
<td>2845.2 ± 401.9</td>
<td>2210.2 ± 429.0</td>
</tr>
<tr>
<td>Middle-dose crocetin</td>
<td>110.3 ± 21.9</td>
<td>6.7 ± 1.9</td>
<td>2994.7 ± 462.5</td>
<td>2543.4 ± 400.2</td>
</tr>
<tr>
<td>High-dose crocetin</td>
<td>122.2 ± 26.3</td>
<td>5.6 ± 1.2</td>
<td>3504.7 ± 459.9</td>
<td>2782.3 ± 378.3</td>
</tr>
</tbody>
</table>

3, P < 0.05 compared with sham-operated group; 4, P < 0.05 compared with model group; a, P < 0.05 compared with low-dose crocetin group; b, P < 0.05 compared with middle-dose crocetin group. LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; (+dp/dt)max, maximum left ventricular systolic/diastolic rate.

Table 2. Levels of myocardial injury markers in different groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>LDH (U/L)</th>
<th>CK-MB (U/ml)</th>
<th>cTnI (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham-operated</td>
<td>1486.6 ± 324.36</td>
<td>3.6 ± 0.5</td>
<td>25.3±2.1</td>
</tr>
<tr>
<td>Model</td>
<td>3152.8 ± 454.3</td>
<td>5.6 ± 1.3</td>
<td>67.8±5.4</td>
</tr>
<tr>
<td>Low-dose crocetin</td>
<td>2864.6 ± 469.9</td>
<td>5.5 ± 0.8</td>
<td>60.0±4.3</td>
</tr>
<tr>
<td>Middle-dose crocetin</td>
<td>2379.3 ± 349.9</td>
<td>4.6 ± 0.8</td>
<td>50.0±6.2</td>
</tr>
<tr>
<td>High-dose crocetin</td>
<td>2016.6 ± 379.5</td>
<td>4.2 ± 0.6</td>
<td>37.5±4.2</td>
</tr>
</tbody>
</table>

3, P < 0.05 compared with sham-operated group; 4, P < 0.05 compared with model group; a, P < 0.05 compared with low-dose crocetin group; b, P < 0.05 compared with middle-dose crocetin group. LDH, lactate dehydrogenase; CK-MB, creatine kinase-MB; cTnI, cardiac troponin I.

Table 3. Serum TNF-α, IL-1β and IL-6 levels in different groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>TNF-α (pg/ml)</th>
<th>IL-1β (pg/ml)</th>
<th>IL-6 (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham-operated</td>
<td>18.0 ± 2.5</td>
<td>58.4 ± 12.1</td>
<td>44.4 ± 9.1</td>
</tr>
<tr>
<td>Model</td>
<td>140.9 ± 25.4</td>
<td>183.5 ± 32.0</td>
<td>328.8 ± 49.8</td>
</tr>
<tr>
<td>Low-dose crocetin</td>
<td>123.7 ± 22.2</td>
<td>149.0 ± 26.7</td>
<td>222.5 ± 35.1</td>
</tr>
<tr>
<td>Middle-dose crocetin</td>
<td>101.9 ± 14.9</td>
<td>113.9 ± 20.4</td>
<td>215.7 ± 32.6</td>
</tr>
<tr>
<td>High-dose crocetin</td>
<td>75.8 ± 10.1</td>
<td>101.6 ± 16.8</td>
<td>190.3 ± 29.2</td>
</tr>
</tbody>
</table>

3, P < 0.05 compared with sham-operated group; 4, P < 0.05 compared with model group; a, P < 0.05 compared with low-dose crocetin group; b, P < 0.05 compared with middle-dose crocetin group. TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; IL-6, interleukin-6.
Protective effect of crocetin on MIRI

Model group, the serum TNF-α level in middle- and high-dose crocetin groups, and IL-1β and IL-6 levels in 3 crocetin groups were significantly decreased, respectively (P < 0.05).

3.5 Effects of crocetin on myocardial SOD, GSH-Px and MDA levels in MIRI rats

Table 4 showed that, compared with sham-operated group, in model group the myocardial SOD and GSH-Px levels were significantly decreased, respectively (P < 0.05), and the myocardial MDA level was significantly increased (P < 0.05). Compared with model group, the SOD level in middle- and high-dose crocetin groups, and GSH-Px level in 3 crocetin groups were significantly increased, respectively (P < 0.05), and the MDA level in 3 crocetin groups was significantly decreased, respectively (P < 0.05).

3.6 Effects of crocetin on myocardial Bcl-2 and Bax protein expression in MIRI rats

Figure 2 showed that, compared with sham-operated group, in model group the myocardial Bcl-2 protein expression level was decreased, and the Bax protein expression level was increased. Compared with model group, the Bcl-2 level in treatments groups was increased, and the Bax level was decreased. The Bcl-2/Bax ratio in model group was 0.7 ± 0.3, significantly lower than 2.1 ± 0.5 in sham-operated group (P < 0.05). The Bcl-2/Bax ratio in middle- and high-dose crocetin groups was 1.1 ± 0.3 and 1.6 ± 0.5, respectively, significantly higher than model group, respectively (P < 0.05).

3.7 Effects of crocetin on myocardial Akt and p-Akt protein expression in MIRI rats

As shown in Figure 3, the myocardial Akt protein expression had no obvious change among different groups. Compared with sham-operated group, the myocardial p-Akt protein expression level in model group was decreased, and that in treatments groups was increased compared with model group. The p-Akt/Akt ratio in model group was 0.4 ± 0.1, significantly lower than 1.1 ± 0.1 in sham-operated group (P < 0.05). The p-Akt/Akt ratio in middle- and high-dose crocetin groups was 0.5 ± 0.1, 0.7 ± 0.1 and 0.8 ± 0.1, respectively, significantly higher than model group, respectively (P < 0.05).

Table 4. Myocardial SOD, GSH-Px and MDA levels in different groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>SOD (U/mgprot)</th>
<th>GSH-Px (U/mgprot)</th>
<th>MDA (mmol/mgprot)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham-operated</td>
<td>208.6 ± 23.4</td>
<td>154.0 ± 20.5</td>
<td>3.8 ± 0.5</td>
</tr>
<tr>
<td>Model</td>
<td>149.3 ± 17.2a</td>
<td>92.6 ± 13.5a</td>
<td>9.1 ± 1.1a</td>
</tr>
<tr>
<td>Low-dose crocetin</td>
<td>157.5 ± 14.6a</td>
<td>105.4 ± 13.1ab</td>
<td>6.9 ± 0.8ab</td>
</tr>
<tr>
<td>Middle-dose crocetin</td>
<td>168.7 ± 19.1abc</td>
<td>127.2 ± 14.7abc</td>
<td>5.8 ± 0.7abc</td>
</tr>
<tr>
<td>High-dose crocetin</td>
<td>189.1 ± 12.3abcd</td>
<td>138.8 ± 18.1abcd</td>
<td>4.5 ± 0.7abcd</td>
</tr>
</tbody>
</table>

*P < 0.05 compared with sham-operated group; †P < 0.05 compared with model group; ‡P < 0.05 compared with low-dose crocetin group; §P < 0.05 compared with middle-dose crocetin group. SOD, superoxide dismutase; GSH-Px, glutathione peroxidase; MDA, malondialdehyde.
4 Discussion

With the application of thrombolytic treatment, coronary artery bypass, percutaneous coronary angioplasty and other vascular reperfusion therapies, the blood supply of myocardial ischemic tissue can be restored. The changes in the period of myocardial ischemia have laid the foundation for the occurrence of reperfusion injury. The reperfusion injury is the continuation, expansion and deterioration of ischemic injury (Jennings, 2013). Therefore, searching for drugs that effectively prevent MIIR has become the research focus of medical scientists. This study investigated the protective effect of crocin on experimental MIIR in rats. Results showed that, compared with model group, the LVSP, +dp/dt_{max}, and -dp/dt_{max} in crocin groups were significantly increased, and the myocardial infarction size in crocin groups was significantly decreased. In addition, compared with model group, the serum levels of myocardial injury markers in crocin groups were significantly decreased. This indicates that, the crocin pretreatment can reduce the myocardial infarction, improve the cardiac systolic and diastolic function, and mitigate the MIIR.

After myocardial ischemia-reperfusion, the calcium overload, oxygen free radical generation and energy metabolism disorder occur, which are the main causes of MIIR (Inci et al., 2001). TNF-α is a pro-inflammatory factor with negative inotropic action, and is the starting factor of the inflammatory cascade reaction. TNF-α can inhibit the contractile force of cardiac myocytes, thus causing cardiac dysfunction and myocardial injury (Chen et al., 2013). IL-1β is in the upstream factor of inflammatory cascade. It can be produced at the early stage of MIIR. When myocardial injury occurs, the continuous increase of IL-1β level can cause series of pathophysiological changes which reduce the myocardial contractility and aggravate the inflammatory response, ischemia-reperfusion injury and arrhythmia (Xu et al., 2008). IL-6 is one of the important inflammatory mediators produced by leukocytes and endothelial cells, and is at the pivot of inflammation regulation. Compared with C-reactive protein and creatine phosphokinase, IL-6 is more sensitive to the stress response and myocardial injury (McGinnis et al., 2015). In this study, compared with model group, the serum TNF-α, IL-1β and IL-6 levels in crocin groups were significantly decreased. This indicates that, crocin can decrease the inflammatory response, thus alleviating the MIIR in rats.

It is found that, when the blood supply is interrupted and the energy supply is reduced, the function of oxygen free radical scavenging enzymes, such as catalase, SOD and GSH-Px, is reduced or lost, resulting in increase of oxygen free radicals. When the blood supply is restored, a large number of oxygen free radicals will generate and accumulate, which leads to the lipid peroxidation (Zhang et al., 2003). MDA is the last metabolite of lipid peroxidation induced by oxygen free radicals, and its activity reflects the degree and content of lipid peroxidation of oxygen free radicals. Detection of these indexes can directly reflect the ability of scavenging oxygen free radicals in the body (Tsikas, 2017). Results of this study showed that, compared with model group, the SOD and GSH-Px levels in crocin groups were significantly increased, and the MDA level was significantly decreased. This indicates that, crocin has the ability of scavenging radical and reducing lipid peroxidation, thus playing a role in alleviating the MIIR.

Phosphatidylinositol 3-kinase and protein kinase B (PI3K/Akt) signaling pathway plays a key role in cell proliferation, metabolism, and apoptosis (Ma et al., 2013). Bcl-2 family is an important target on the PI3K/Akt signaling pathway (Jin et al., 2004). Bcl-2 and Bax are the core members of the Bcl-2 family. They play an important role in the development and development of cell apoptosis. Bcl-2 is the main apoptosis-inhibiting protein. It participates in the regulation of apoptotic signal by regulating the integrity of mitochondrial membrane, promote the viability of cardiomyocytes, and inhibit their apoptosis. On the contrary, Bax acts with Bcl-2 by forming the heteromeric dimers, thus inhibiting Bcl-2 activity and promoting the cell apoptosis (Korsmeyer et al., 1993). After myocardial ischemia, both Bcl-2 and Bax are expressed in cardiomyocytes. The over expression of Bcl-2 can significantly inhibit the apoptosis of cardiomyocytes after MIIR, and reduce the infarction size. The balance between Bcl-2 and Bax plays an important role in the regulation of cell apoptosis. The decrease of Bcl-2/Bax ratio indicates the induction of apoptosis, and the increase of Bcl-2/Bax ratio indicates the inhibition of apoptosis (Schulz et al., 2012). Study has shown that, Akt activation (p-Akt) can promote the formation of Bcl-2 protein, and inhibit the formation of Bax, Bad and Caspases, thus inhibiting the cell apoptosis (Tang et al., 2006). In this study, compared with sham-operated group, in model group the myocardial Bcl-2 protein expression level was decreased, and the Bax protein expression level was increased. In addition, the myocardial p-Akt protein expression level was decreased. Compared with model group, in crocin groups the Bcl-2 protein level was increased, the Bax protein level was decreased, and the p-Akt protein was increased. This indicates that, the decreased phosphorylation of Akt and increased myocardial apoptosis are involved in the process of MIIR. Crocin can increase the phosphorylation of Akt and reduce the myocardial apoptosis, thus alleviating the MIIR.

In conclusion, crocin from *Crocus sativus* L. has protective effects on MIIR in rats. The mechanism may be related to its resistance of inflammatory response, oxidative stress and myocardial apoptosis, and activation of PI3K/Akt signaling pathway in myocardial tissue. This study has provided an experimental basis for the clinical application of crocin to prevention and treatment of MIIR. The limitations of this study are as follows: Firstly, the correlations among different indexes have not been discussed. Secondly, there are may be other mechanisms of crocin alleviating MIIR. These issues need to be further investigated.

References


